Of note, a recent paper has revealed that 9 % of the 65 evaluated BTC cases showed ROS1 rearrangements at genetic analysis [23]: as in non-small cell lung cancer [28], this may pave the way for the clinical evaluation of specific inhibitors in aBTC patients. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.